Compositions and methods for preventative treatments for mucosal associated ailments
The administration of NTHi formulations enhances the mucosal immune system, improving health and resilience against respiratory infections by stimulating specific T cells and activating innate immunity, addressing the limitations of antibiotic treatments.
Patent Information
- Application Number
- PCT/AU2024/050460
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-12
- Filing Date
- 2024-05-10
- Publication Date
- 2024-11-21
AI Technical Summary
Current treatments for respiratory diseases and disorders, such as bacterial infections in the upper and lower airways, often rely on antibiotics, which have limited effectiveness and can lead to resistance, partial control, or failure to suppress infections.
Administering a formulation comprising Non-Typable Haemophilus influenzae (NTHi) to enhance the mucosal immune system, stimulating specific T cells to activate innate immunity and promote immune resilience, thereby improving health and wellness before exposure to bacterial or viral infections.
The NTHi formulation primes the mucosal immune system, enhancing the body's ability to resist or ameliorate the effects of subsequent infections by boosting cell-mediated immune responses and maintaining mucosal barriers, providing prolonged immune resilience against respiratory pathogens.
Smart Images

Figure IMGF000060_0001 
Figure IMGF000060_0002 
Figure IMGF000061_0001
Abstract
Description
Compositions and Methods for Preventative Treatments for Mucosal Associated Ailments TECHNICAL FIELD
[0001] The inventor has determined that the health or wellness of a normal individual (i.e. an individual that is not suffering from a mucosal disease, condition or disorder within the respiratory, digestive, or urogenital tracts (or more preferably only within the respiratory tract), of bacterial or viral origin) can be improved by priming or enhancing the individual’s trained innate immune system using a formulation as herein described. Priming or enhancing an individual’s trained innate immune system before an individual that is not suffering from a mucosal disease, condition or disorder within the respiratory, digestive, or urogenital tracts (or more preferably within the respiratory tract), of bacterial or viral origin, provides the individual with a means to (a) resist or substantially resist a subsequent disease, condition or disorder of bacterial or viral origin, or (b) to ameliorate the effect or severity of a subsequent bacterial or viral challenge to the individual.
[0002] Accordingly, the present invention provides formulations and methods of using those formulations in the enhancement of, or improvement of, health and wellness of normal individuals. The formulations depend on the use of strains of Non- Typable Haemophilus influenza (NTHi); particularly the whole organism, fragments thereof, genomic sequences, polypeptides, and nucleotide sequences encoding polypeptides thereof. More specifically, the invention encompasses methods for enhancing the health and wellness of a normal individual (i.e. an individual that is not suffering from a mucosal disease, condition or disorder within the respiratory, digestive, or urogenital tracts (or more preferably only within the respiratory tract), of bacterial or viral origin) using formulations of the invention. BACKGROUND ART
[0003] The following discussion of the background art is intended to facilitate an understanding of the present invention only. The discussion is not an acknowledgement or admission that any of the material referred to is or was part of the common general knowledge as at the priority date of the application.
[0004] Generally, mucosal surfaces (such as, those found in the gut and respiratory tract) are inhabited by niche-specific communities of bacteria, commonly referred to as mucosal microbiota, which ensure a balance between pathology and immunity. That is, it is thought that mucosal microbiota is a kind of “gatekeeper” that provide resistance to colonisation by pathogens.
[0005] Mucosal surfaces are constantly under challenge by a diverse range of pathogens from the environment. A host’s first line of defence is the mucus layer which contains B cells that produce immunoglobulins to control the establishment of pathogens. Epithelial cells are also involved in this defence preventing pathogens from colonizing the mucus tissue. Mucosal microbiota drive the activity of this first line defence by stimulating different aspects of the immune system which contributes to immune maturation, tolerance and resistance to bacterial infection.
[0006] In the 1970’s a concept known as Common Mucosal Immunological System (CMIS) was proposed, which suggested that the mucosal immune system is one large, interconnected network and that the individual components of the system are very efficient at sharing information distally. As a result, mucosal surfaces have been considered as a global organ exhibiting a close and complex interrelationship with mucosal microbiota (commensal bacteria) and thus present a common mucosal immune system.
[0007] The concept of the CMIS underpinning the distribution of mucosal protection, has gained widespread acceptance over the past 40 years, although many additional discoveries including regional and environmental influences have modified and expanded the concept. For example, a directional flow of B-lymphocytes from gut-associated lymphocyte tissue to the bronchus mucosa has been established in a sheep model. Similarly, various studies have suggested that T cells participate in inter-mucosal cell traffic by mucosa-seeking T cells.
[0008] In the last two decades a plethora of different immunological models and methods have been proposed to positively influence the delicate mucosal microbiota balance in favour of providing a treatment for inflammation caused by persistent pathogen.
[0009] One such product was BRONCOSTAT™, which provided an enteral non- adjuvanted monobacterial vaccine comprising killed NTHi. This therapeutic provided a treatment against acute episodes of infection in patients with long term chronic lung disease compared to a conventional adjuvanted polybacterial vaccine.
[0010] NTHi is the most common pathogenic bacteria associated with chronic bronchitis (CB) (Sethi and Murphy, (2001), Clin. Microbiol. Rev.14:336-363).
[0011] NTHi can be found in the upper airways (e.g., nose, middle ear, throat and sinuses) of healthy patients and patients with CB (Sethi and Murphy, (2001), Clin. Microbiol. Rev. 14:336-363) as well as in several locations of the respiratory tract, including the lumen, adhering to mucosal epithelial cells in the interstitium of the submucosa (Moller et al, (1998), Am. J. Respir. Crit. Care Med.157:950-56).
[0012] Studies of non-obstructive and obstructive CB have observed that a large proportion of patients have persistent infection with NTHi (Murphy et al, (2004), Am. J. Respir. Crit. Care Med.170:266-72).
[0013] Existing NTHi research has established that oral inactivated bacteria provide a treatment against exacerbations in subjects with COPD that have NTHi present in their airways at a considerable level. Further studies in animal models and humans using orally administered whole cell killed NTHi, have established that oral NTHi immunotherapy acts by driving multiple physiological immune pathways. In this respect, the bronchus microbiome is controlled by aspirated antigen delivered to Peyer’s patches, which in turn stimulate T helper 17 (Th17) cells that home to the bronchus. Within the bronchus, Th17 cells recruit and activate phagocytic cells that reduce colonizing bacteria. In this respect, Th17 cells serve as a subset of pro- inflammatory T helper cells that aid in maintaining mucosal barriers and contribute to pathogen clearance at mucosal surfaces. The loss of Th17 cell populations at mucosal surfaces is also linked to chronic inflammation and microbial translocation.
[0014] Focusing on the respiratory system, the mucosal immune protection system thus operates by two main pathways. First, a pathway for particular antigens (such as bacteria) that involves Peyer’s patches as described above. Second, a pathway for soluble antigen, involving an extensive network of high turnover dendriticcells (DC). These DC interact with T cells in regional nodes, activating regulator T cells resulting in down regulation as the predominant response.
[0015] Importantly, for the first pathway, a threshold level of antigen is required before the mucosal epithelial DC network activates. This can be best understood by considering the dynamic between abnormal biota within a damaged airway and the restraining “bronchus to gut to bronchus” immune response that follows infection with an intercurrent pathogen. An increased delivery of Th17 cells into the bronchus lumen causes an excessive and inappropriate flux of neutrophils, detected clinically as an increase in volume and purulence of sputum. The DC “carpet” is, in this circumstance, exposed to multiple stimuli with a consequent reduction in inhibition and even an additional pro-inflammatory effect contributing to sputum purulence.
[0016] The immunological responses in the respiratory system (such as in subjects with COPD) and how these responses are modulated is directly determined by the level of NTHi and aspiration of bronchus content into gut which activates Payer’s patches from where Th17 cells traffic their effect to the airways. However, the animal models have also showed that to get rapid clearance of live NTHi present in a subject’s airways, dead NTHi must be artificially put into the airway, to expand and activate Th17 cells migrating from the Peyer’s patches.
[0017] Treatments for respiratory diseases and disorders such as bacterial infections of the upper and lower airways vary. Classically, these different types of persistent infections have been treated with antibiotics, which have limited benefit. Antibiotics have, however, an important place in such therapy, but resistance, partial control or failure to suppress infection with the use of antibiotics alone is common.
[0018] The present invention seeks to address, or at least ameliorate, one or more of the deficiencies of the prior art mentioned above, or to provide the consumer with a useful or commercial alternative to one or more prior art technologies in this field. SUMMARY OF INVENTION
[0019] In accordance with the present invention, the inventor has determined that by enhancing the effect of mucosal microbiota in a normal individual, the inventor can improve the health and improve wellness of that individual. In particular, the inventorhas determined that a formulation comprising Haemophilus influenzae preferably non- typable Haemophilus influenza (NTHi) when administered to individuals not suffering from a mucosal disease, condition or disorder, (preferably not suffering from a disease of the respiratory tract) of bacterial or viral origin, can improve the health (e.g. immunological health) or wellness of the individual by priming the mucosal microbiota.
[0020] Preferably the normal individual is given NTHi at a dose range of from about 108to about 1015killed cells, more preferably from about 109to about 1013killed cells, preferably as a plurality of doses at least two weeks before measuring the individual’s health and wellness or two weeks before the individual is exposed to a bacterial or viral infection of the mucosa.
[0021] By improving a normal individual’s health in such a manner, the individual’s mucosal immune system becomes primed for resisting subsequent infection presenting the individual with greater capacity to either (a) resist a disease, condition or disorder of bacterial or viral origin, or (b) to ameliorate the effect of a bacterial or viral challenge to the individual.
[0022] More specifically, oral NTHi stimulates delivery of specific T cells that migrate to airway to promote health by shifting immune resilience in favour of the individual. The key to immune resilience is delivery of specific (adaptive immunity) T cells to locate via receptors in small vessels within the bronchus mucosa, where they trigger learned innate immunity to reduce the load of antigens (bacteria) within the mucosal compartment.
[0023] Animal and human studies conducted by the inventor have revealed that specific T cells derived from Peyer’s patches must enter the mucosal space and then be re-stimulated by NTHi within the local microbiome. This requires binding of specific T cells to receptors in the small blood vessels within the bronchus.
[0024] When a normal individual is given Buccaline (Haemophilus influenzae, pneumococci (I, II, III), Staphylococcus aureus and Streptococcus agalactiae) tablets, which purports to provide a oral protection against bacterial complications of colds like sneezes, runny noses, sore throats and coughs, the individual is being given a non- specific stimulant that produces a small number of NTHi specific T cell, which levels are so dilute in the Peyer’s patches and mucosa they are unable to cause specificstimulation within the bronchus. Yet, when oral NTHi is given to normal individuals a more efficient binding is occurring causing a greater number of NTHi specific T cell causing greater stimulation of the peyers patches and greater immune resilience in the mucosa. This result was totally unexpected by the inventor.
[0025] Thus, in a first aspect, the invention provides a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual an immunologically stimulatory preparation of a Haemophilus influenzae strain, preferably NTHi strain, at a dose range of from about 108to about 1015killed cells prepared for administration as an oral or nasal dosage. Preferably the immunologically stimulatory preparation is administered as a daily dose (which might be prepared and presented as multiple dosage forms leading to a delivered dose range of from about 108to about 1015killed cells) on at least 2 consecutive days at least two weeks before measuring the individual’s health and wellness or two weeks before the individual is exposed to a bacterial or viral infection of the mucosa.
[0026] The method of the first aspect of the invention relies upon a health and wellness enhancing NTHi preparation that activates or enhances an individual’s native mucosal immune system in the absence of a bacterial or viral challenge (i.e. it provides an immunologically stimulatory preparation). It is speculated by the inventor that the immunological stimulatory affects are attributed to enhancing or priming of the cell mediated immune response, therein boosting the immune system ability to protect against subsequent infections in the mucosa, such as lung and gut. By priming an individual’s immune system in this manner, the inventor can improve the health and wellness of an individual.
[0027] More particularly the inventor has discovered that in any normal individual there is quite a different dynamic in the immunological capacity of those cells in blood as they transit from the peyers patch to the lung. That is, normal individuals have a different immunological capacity relative to a diseased individual. For example, when individuals exposed to a persistent COPD infection are feed NTHi tablets according to the methods described herein there is a brisk immunological response in the COPDpatients due to high number of circulating T cells. Any increase in immunological response with subsequent oral NTHi is small but significant, due to a combination of reaching capacity and suppression (which goes with the territory). The immune cells develop an immunological resilience because of diseased airways.
[0028] In contrast in “normal” individuals that have been treated with the formulation of the invention there is hardly any response after 6 days after the first oral NTHi, but marked response to subsequent oral NTHi, indicating highly effective generation of sensitive T cells enroute to mucosa, to shift resilience towards “derisking”, to buffer against subsequent viral infections.
[0029] After about 3 months the COPD patient is producing circulating T cells due to their continued swallowing of microbiome, there is no established circulating pool of peyers patch-derived T cells to maintain T cell delivery. This is significant because with high circulating pools of peyers patch-derived T cells normal individuals get protection for at least 10 months (but NOT more than one year). This indicates that more frequent oral courses of the invention in normal subjects will maintain derisked optimal immune resilience ie health promotion.
[0030] The NTHi preparation used in the invention is prepared from NTHi bacterium that are alive and viable, dead, attenuated or non-viable or inactivated or a mixture of these different states. Preferably, a substantial portion of the NTHi bacterium in the preparation are inactivated, attenuated or non-viable or a mixture of these viability states. More preferably, a substantial portion of the NTHi bacterium in the preparation are non-viable, dead bacteria. Most preferably, the NTHi preparation is an attenuated or non-viable or inactivated NTHi strain.
[0031] In an alternate form, the first aspect of the invention, resides in the use of an immunologically stimulatory preparation of a Haemophilus influenzae strain, preferably NTHi strain, for the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0032] In yet another form, the invention resides in a health and wellness formulation suitable for administration to an individual for improving the health and orwellness of the individual, which formulation is prepared as an immunologically stimulatory preparation of a Haemophilus influenzae strain, preferably NTHi strain, with a dose range of from about 108to about 1015killed cells prepared for administration as an oral or nasal dosage. The individual being treated by the formulation will not be suffering from a mucosal disease, condition, or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0033] In addition, the inventor has revealed that where a formulation comprising Haemophilus influenzae preferably NTHi is combined with vitamin A and or vitamin D either alone or in combination with one or more other vitamins selected from vitamin C or Z, the formulation provides enhanced means to improve the health (e.g. immunological health) or wellness of the individual.
[0034] In a preferred form, the formulation described above includes a therapeutically effective amount of zinc, or a zinc ionophore (such as a polyphenol), which aides in the prevention of mucosal diseases, conditions or disorders associated with a subject’s mucosa (including, without limitation, respiratory, digestive, and urogenital tracts).
[0035] In a second aspect, a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain, with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof, prepared for administration as an oral or nasal dosage.
[0036] This aspect of the invention also incorporates a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder ofthe respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain, prepared for administration as an oral or nasal dosage, with a dose range of from about 108to about 1015killed cells prepared for administration as an oral or nasal dosage; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof.
[0037] In a further embodiment of the second aspect of the invention resides in the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, with a dose range of from about 108to about 1015killed cells prepared for administration as an oral or nasal dosage; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and in the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0038] In a further embodiment of the second aspect of the invention resides in the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, , with a dose range of from about 108to about 1015killed cells prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and in the manufacture of a medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition ordisorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0039] In yet another embodiment of the second aspect the invention resides in an immune health and wellness enhancing formulation for use in a normal individual, said formulation comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain, with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof, wherein the formulation is prepared for administration as an oral or nasal dosage.
[0040] In an alternate form of the above embodiment the invention resides in an immune health and wellness enhancing formulation for use in a normal individual, said formulation comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain, with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal dosage; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof.
[0041] According to a third aspect of the invention there is provided a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, with a dose range of from about 108to about 1015killed cells prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol),
[0042] According to an alternate form of the third aspect of the invention there is provided a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), wherein the formulation is prepared for administration as an oral or nasal dosage.
[0043] In an embodiment of the third aspect, the invention resides in the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), in the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0044] In an alternate embodiment of the third aspect, the invention resides in the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, prepared for administration as an oral or nasal therapeutic with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; andc. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), in the manufacture of a medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0045] In another embodiment of the third aspect of the invention, the formulation includes zinc, or a zinc ionophore (such as a polyphenol), which enhances the benefit or effect of the formulation on an individual’s mucosal immune system. According to this embodiment the formulation comprises: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, prepared for administration as an oral or nasal therapeutic with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
[0046] In yet another embodiment, the immune health and wellness enhancing formulation comprises: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), wherein the formulation is prepared for administration as an oral or nasal dosage.
[0047] In a fourth aspect of the invention, the invention resides in a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual:a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
[0048] In an alternate form of the fourth aspect of the invention, the invention resides in a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), wherein the formulation is prepared for administration as an oral or nasal dosage.
[0049] The above embodiment of the fourth aspect of the invention also incorporates the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol),in the manufacture of a medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0050] The above embodiment of the second aspect of the invention also incorporates the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), for the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0051] According to the fourth aspect of the invention, the formulation comprises: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, with a dose range of from about 108to about 1015killed cells prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
[0052] According to yet another embodiment, the fourth aspect of the invention includes a formulation comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, with a dose range of from about 108to about 1015killed cells prepared for administration as an oral or nasal therapeutic; andb. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
[0053] In a fifth aspect, the invention provides a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual an amount of the formulation described in the second, third or fourth aspects of the invention or their embodiments, sufficient to stimulate an individual’s cell mediated immune system.
[0054] In a sixth aspect, the invention is directed to a method of preparing a formulation wherein the method including the steps of: (i) culturing live cells of a selected NTHi bacterium; (ii) inactivating the NTHI bacterium by killing the cells; and (iii) formulating the inactivated bacterium into a formulation with the other constituents of the formulation.
[0055] In a seventh aspect, the invention is directed to a kit for improving an individual’s health and or wellness comprising: an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, prepared for administration as an oral or nasal therapeutic.
[0056] In an embodiment of the seventh aspect the invention is also directed to a kit for improving an individual’s health and or wellness comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, with a dose range of from about 108to about 1015killed cells prepared for administration as an oral or nasal therapeutic; and b. a therapeutically effective amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof.
[0057] Further features of the present invention are more fully described in the following description of several non-limiting embodiments thereof. BRIEF DESCRIPTION OF THE FIGURES
[0058] The disclosure will provide details in the following description of preferred embodiments with reference to the following figures.
[0059] Figure 1 illustrates Higher Specific Antigen-Reactive T Cell / Non-Specific T Cell Ratio Following Monobacterial Oral Immunisation (NTHi) Compared to Multi- Bacterial Compound (Buccaline) DETAILED DESCRIPTION OF THE INVENTION
[0060] The inventor has determined that the health and wellness of a normal individual can be improved by priming or enhancing the mucosal microbiota absent infection therein providing a means to (a) resist or substantially resist a subsequent disease, condition or disorder of bacterial or viral origin, or (b) to ameliorate the effect or severity of a subsequent bacterial or viral challenge to the individual.
[0061] At a micro-level the inventor presently believes that formulations of the invention enhance an individual’s immune response, notwithstanding the individual is not challenged by a pathogen, by activating Th17 cells that aid in maintaining mucosal barriers and contribute to pathogen clearance at mucosal surfaces. In this respect, the inventor believes that the NTHi preparation in the formulation induces trained immunity, conferring non-specific protection from subsequent infections. Trained innate immunity is an immunological memory occurring in innate immune cells or non- immune cells. That is, innate immune responses have adaptive characteristics that can lead to protection against subsequent unrelated infections.
[0062] Put another way, generally the immune pathway is activated when a threshold level of antigen causes activation of the mucosal epithelial DC network. This can be best understood by considering the dynamic between abnormal biota within a damaged airway and the restraining “bronchus to gut to bronchus” immune response that follows infection with an intercurrent pathogen. Increased delivery of Th17 cells into the bronchus lumen causes an excessive and inappropriate flux of neutrophils,detected clinically as an increase in volume and purulence of sputum. The DC “carpet” is, in this circumstance, exposed to multiple stimuli with a consequent reduction in inhibition of the immune response and even an additional pro-inflammatory effect contributing to sputum purulence.
[0063] The immunological responses in the respiratory system and how these responses are modulated is directly determined by the level of NTHi and aspiration of bronchus content into the gut, which activates peyer’s patches from where Th17 cells traffic their effect to the airways. Inventor has identified that to get rapid clearance of live NTHi present in a subject’s airways, dead NTHi must be artificially introduced into a normal individual to expand and activate Th17 cells migrating from the peyer’s patches.
[0064] Thus, trained innate immunity at mucosal surfaces is dependent on delivery of adaptive immunity in the form of Th17 cells generated in peyer’s patches. Inventor believes that this process is driven by GM-CSF released from T cells as well as an increased release of gamma interferon (for example, protective against viruses) and a reduction in IL-10 (which limits adaptive immunity). GM-CSF therefore provides a causal link between specific Th17 cells arriving in mucosa from peyer’s patches (which secrete GM-CSF) to activate “learned innate immunity” promoting in immune resilience in normal healthy people.
[0065] GM-CSF is a pleiotropic cytokine regulator of immune and nonimmune cells that is required for terminal differentiation of alveolar macrophages in the lungs and regulates the basal functional capacity of circulating neutrophils in humans. Normally, GM-CSF is present at very low or undetectable levels in the serum and tissues in humans. Nonetheless, these low levels are critical.
[0066] Importantly, IL-10 secretion down regulates the Th17 cells which arrests the pulse of Th17 cells arriving in the mucosa causing “termination” of the immune response.
[0067] Therefore, to induce durable protection in normal healthy individuals, dead NTHi should be administered to an individual to expand and activate Th17 cells migrating from the peyer’s patches permitting Th17 cells to pass on protection to innateimmunity via GM-CSF (a known connector in other circumstances between Th17 cells).
[0068] It is thought by the inventor that if the trained innate immunity is not controlled, IL-1 drives phenotypic change in neutrophils (cells of innate immunity) which self-perpetuate by making their own IL-1.
[0069] Further, Toll-like receptors (TLR) are molecular receptors through which the immune system becomes aware of a risk from pathogenic organisms or endogenous threats. Numerous roles of TLRs have been identified, including recognition of self and non-self-antigens; detection of invading pathogens; bridging the innate and adaptive immunity; and regulation of cytokine production, proliferation, and survival, commonly referred to as the TLR signalling pathway, which results in the production of various cytokines and chemokines. Ultimately, the TLR signalling pathway leads to the induction or suppression of genes that fine-tune the inflammatory response.
[0070] It is suggested by the inventor that the formulations of the present invention influence the Toll-like receptor signalling pathway, resulting in an improved immune response in individuals when confronted with new clinical conditions especially those associated with inflammatory diseases, conditions or disorders associated with a subject’s mucosa such as those experienced by patients with respiratory and or gut disorders and or immunosenescence.
[0071] Clinical conditions associated with inflammatory diseases, conditions or disorders associated with a subject’s mucosa such as those experienced by patients with respiratory and or gut disorders may range from (i) normal (i.e. patients that get coughs or purulent sputum every time they have an upper respiratory tract virus infection or where they have an episode of irritable bowel syndrome (IBS) due to altered gut microbiome), to (ii) diseased – (i.e. patients with major underlying pathology (such as, severe structural damage due to inhaled toxins (e.g. COPD or chronic bronchitis); unresolved virus (e.g. SARS-CoV-2 infection) or bacterial infection (e.g. bronchitis); genetic defect leading to poor mucosal clearance of gut microbes (e.g. Crohn’s Disease) or impaired immunity and recurrent H. pylori, and so on).
[0072] In all the above conditions, the accumulated host inflammatory response (e.g., the activation of neutrophils due to Th17 cells or antibodies to colonizing organisms) causes clinical outcomes. The immune response in these situations which is illustrated in Figure 1 include (i) stimulation of Peyer’s patches, which activates a Th17 response in the subject’s mucosa, increasing phagocytosis and increasing interferon levels; and (ii) down regulation of regulatory T cells (Treg cells) in the mucosa responding to the presence of soluble antigens. This response results from a shift in the balance between activation (Th17) and down regulation (Treg cells) of the immune modulators.
[0073] Thus, the invention draws on the use of specific immune enhancers which when administered to one mucosal surface in a subject enhance a Th17 cell response in said subject, which activates a cell mediated immune response at the same or a different mucosal site in the subject therein providing a preventative reaction for an infection or inflammatory condition in the same or a different mucosal site in that subject.
[0074] By priming the immune system in advance of an immunological challenge the inventor believes that they can boost an individual’s immune system’s ability to protect against subsequent infections in the mucosa, such as lung and gut. By priming an individual’s immune system in this manner, the inventor can improve the health and wellness of an individual.
[0075] In addition to the above, older adults are often more susceptible to infections due to the age-related dysregulation and decline of the immune system. This dysregulation is referred to as immunosenescence. Immunosenescence in older adults often results in an increased susceptibility to infectious pathogens and / or poor vaccine responses. It is believed that changes in the adaptive immune system during aging, specifically in T and B cells, influence a person’s response to, for example, vaccines and / or antibiotics. Age related changes in adaptive immunity include alterations in cellular immunity, humoral immunity and possibly changes in lymphatic tissue. Thus, changes in adaptive immunity with age are considered to have an impact on immune cell function, making older adults more susceptible to infections and possibly suffering from long term complications, as well as a weakened vaccineresponse. Furthermore, age also effects the capacity of the CMIS to deliver T cells to the bronchus mucosa. A. General Description
[0076] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. The invention includes all such variation and modifications. The invention also includes all the steps, features, formulations and compounds referred to or indicated in the specification, individually or collectively and any and all combinations or any two or more of the steps or features.
[0077] Each document, reference, patent application or patent cited in this text is expressly incorporated herein in their entirety by reference, which means that it should be read and considered by the reader as part of this text. That the document, reference, patent application or patent cited in this text is not repeated in this text is merely for reasons of conciseness.
[0078] Any manufacturer’s instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention.
[0079] The present invention is not to be confined in scope by any of the specific embodiments described herein. These embodiments are intended for the purpose of exemplification only.
[0080] Unless defined otherwise, technical and scientific terms used herein have the same meaning as commonly understood by a person skilled in the art to which this invention belongs. Also, throughout this specification: a) unless the context requires otherwise, the word “comprise”, or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers; b) the use of the singular includes the plural unless specifically stated otherwise. Also, the use of "or" means "and / or" unless stated otherwise.Furthermore, the use of the term "including", as well as other forms, such as "includes" and "included", is not limiting; and c) relative language such as the words ‘about’ and ‘approximately’ is used. This language seeks to incorporate 10% variability to the specified number or range. That variability may be plus 10% or negative 10% of the number specified.
[0081] The invention described herein also includes various ranges (e.g., dosage, concentration etc.). A range of values includes all values within the range, including the values defining the range, and values adjacent to the range which lead to the same or substantially the same outcome as the values immediately adjacent to that value which defines the boundary to the range. Unless indicated to the contrary, the numerical parameters set forth in the specification and claims are approximations that may vary depending upon the desired properties sought to be obtained by the present invention. Hence “about 80%” means “about 80%” and “80%”. At the very least, each numerical parameter should be construed considering the number of significant digits and ordinary rounding approaches.
[0082] The terms “substantial”, “substantially” and “substantial portion” as used herein represent an amount or portion that is greater than 50% of the whole, for example, greater than 80%, or greater than 90%, or greater than 95%, or greater than 96%, or greater than 97%, or greater than 98%, or greater than 99%, or 100% of the total amount or portion of an element or factor.
[0083] As used herein the term “formulation” generally includes each the constituents being present as separate dosage forms. When administered in this manner the different dosage forms are coadministered. Coadministration includes administering two or more active agents simultaneously, approximately simultaneously within about 1, 5, 10, 15, 20, or 30 minutes of each other, or sequentially in any order within about 1, 5, 10, 15, 20, or 30 hours of each other. In some embodiments, coadministration can be accomplished by coformulation, i.e., preparing a single formulation including both active agents. In other embodiments, the active agents can be formulated separately.
[0084] As used herein the term “individual” means humans and any other animal to which administration of the formulation of the invention is desirable, including mammals and non-mammals such as primates, livestock, companion animals, laboratory test animals, captured wild animals, birds. Thus, the term includes monkeys, humans, pigs, cattle, sheep, goats, horses, mice, rats, guinea pigs, hamsters, rabbits, cats, dogs, chickens, turkeys, ducks, and other poultry.
[0085] As used herein the phrase "normal individual” refers to an individual that is not suffering from a mucosal disease, condition or disorder within the respiratory, digestive, or urogenital tracts, said disease being of bacterial or viral origin. More preferably the phrase means that the individual that is not suffering from a mucosal disease, condition or disorder in the respiratory tract wherein said disease is of bacterial or viral origin. Whether an individual is suffering a from a mucosal disease, condition or disorder can be determined by any means known in the art. Such methods are well known in the art and part of the common general knowledge.
[0086] Preferably the normal individual will be determined by measuring an elevation in the levels of GM-CSF and or a reduction in IL-10 levels.
[0087] During inflammation, GM-CSF is principally produced by T helper cells and acts as a communication conduit between myeloid cells and tissue-invading lymphocytes. GM-CSF is considered an important proinflammatory cytokine.
[0088] Relevantly, GM-CSF is barely detectable in the peripheral blood of healthy normal individuals and is expressed basally in nonsterile tissues such as the lung, gut, and skin. Serum GM-CSF protein concentrations in the healthy normal individuals typically range from 7 to 8.6 pg / mL, with a mean of 7.6 ± 0.8 pg / mL and a median of 7.8 pg / mL
[0089] Methods for measuring GM-CSF include the methodologies disclosed in Borriello, F et al Int J Mol Sci 20 (2019) 834 or alternatively, serum concentrations of free GM-CSF can be measured using Quantikine HS Human GM-CSF ELISA kits (R&D Systems Inc., Minneapolis, U.S.A) according to the manufacturer's instructions.
[0090] According to the invention a normal individual will be one that has a serum GM-CSF measure typically in the range from less than 7 to 8.6 pg / mL, with a mean of7.6 ± 0.8 pg / mL. Preferably a normal individual will have a serum GM-CSF measure of greater than 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9 pg / mL but less than 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, 13, 13.1, 13.2, 13.3, 13.4, 13.5, 13.6, 13.7, 13.8, 13.9, 14, 14.1, 14.2, 14.3, 14.4, 14.5, 14.6, 14.7, 14.8, 14.9, 15.0, 15.1, 15.2, 15.3, 15.4, 15.5, 15.6, 15.7, 15.8 or 15.9 pg / mL wherein the upper range limit must be greater than the lower range limit.
[0091] Alternatively or in addition, a normal individual can be determined by measuring a reduction in IL-10 which mediates suppression of adaptive immunity. Among healthy normal individuals serum IL-10 levels range from 4.8-9.8 pg / ml (mean 7.1, standard deviation 1.5 pg / ml). Therefore levels > or = 10 pg / ml are considered elevated.
[0092] Preferably the IL-10 levels in a normal individual are in a range from greater 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, but less than 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.97, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0 pg / ml
[0093] Serum levels of IL-10 can be quantified using a variety of a sandwich enzyme immunoassay kits such as those manufactured by R&D Systems, Inc., Minneapolis, U.S.A. The minimum detectable dose of IL-10 using the R&D Systems, Inc.is typically less than 3.9 pg / mL.
[0094] In addition to the above the healthy normal individual may be determined by measuring an improvement in the levels of IL-1, TNF, IL-6 inflammatory cytokines,and chemokine for neutrophils (MIP-2 equivalent to IL-8 - chemokine for neutrophils; and MCP-1 - chemokine for macrophages). Generally, one or more of these cytokines or chemokines will be elevated in the presence of inflammatory or viral response. Therefore, a reduction in one or more of these levels is a positive outcome. Put another way, their elevation is reflective of an active inflammatory process underpinning cellular response to live bacteria. Assays for both lung tissue and the Bronchial Washings, and both protein and mRNA analyses may be used and are well known in the art.
[0095] A “mucosal surface” or the “mucosa” refers to any mucous membrane lining of a body cavity or canals in or on a subject. Chiefly this includes, without limitation the respiratory, digestive, and urogenital tracts. Mucous membranes line many tracts and structures of the body, including the mouth, nose, eyelids, trachea (windpipe) and lungs, stomach and intestines, and the vagina, glans penis, anus, ureters, urethra, and urinary bladder.
[0096] As used herein the terms “killed whole cell”, “killed“, and “non-viable” bacteria are intended to refer to the whole cell, which has been rendered inactive and non-viable by any one or more means for inactivating bacteria known in the art. Bacterial viability may be measured by a bacterial growth assay using any means known in the art, for example, using a turbidity measurement assay, plaque assay, etc.
[0097] A whole killed bacterium, or a multiplicity of whole killed bacteria, can be useful as components of a formulation of the invention. These killed, non-viable cell(s) comprise substantially all the components of the native bacterium. Since they comprise all the components of a native bacterium, when a host is presented with a whole killed bacterium, they are exposed to numerous bacterial antigens from which they may gain immunity.
[0098] An “inactivated” bacterium refers to a bacterium that has been inactivated by, for example, exposure of the bacterium to an agent that can disrupt the bacterial cell membrane. Such inactivated bacteria are useful in the inventive formulations as they contain antigens, but are generally incapable of infecting the host. In some cases, however, an inactivated bacterium may not be fully inactivated, i.e., some bacterialcells may remain after inactivation which can infect a host. In such cases it is useful to start with a bacterium of the invention which has been subjected to a viability assay, as this will assess the viability of the bacterium as being sufficiently low (i.e., less than 20%, or less than 10% or less than 5%, or less than 1%, up to 0.01% of the viability of a live, non-attenuated bacterium of the invention) to avoid undesirable side effects in the subject and ensure that any remaining active bacterium has a reduced replication rate and, therefore, a reduced infectivity.
[0099] In the context of the present invention, a bacterium has a “reduced replication rate”, or “reduced replication” if it has a reduced ability to replicate under physiological conditions as comparted to a non-attenuated, live, viable bacterium of the invention under equivalent conditions.
[0100] An “attenuated” bacterium is a bacterium which is less virulent and less able to infect its host than a wild type bacterium of the same strain. A bacterium of the invention may be attenuated. For example, a bacterium of the invention may include a mutation in at least one gene, mutation of which reduces its ability to infect or otherwise cause disease or disorder in a human host. An exemplary mutation in one or more genes reduces the rate at which the bacterium can replicate and / or produce toxins and other pathological markers. An attenuated bacterium may be a bacterium that has been exposed to a process of attenuation. The process of “attenuation” takes an infectious bacterium and alters it so that it becomes harmless or between 70% and 100 % less virulent than a corresponding non-attenuated, live, viable bacterium.
[0101] Whole attenuated bacterial cells can be useful as components of a formulation of the invention as they comprise substantially all the components of a native bacterium. Since they comprise all the components of a native bacterium, when a host is immunised with a whole bacterium, they are exposed to numerous antigens to which they may gain immunity.
[0102] The “virulence” of a bacterium provides a quantitative measure of the pathogenicity of the bacterium, or the likelihood of the bacterium for causing disease. Bacterial “virulence factors”, or “infectivity factors” are molecules produced by a microorganism that evoke diseases and disorders. Examples are toxins, surface coats that inhibit phagocytosis, and surface receptors that bind to host cells. Assays thattest and quantify the virulence and toxicity of bacterial strains in different organs and at various times post-inoculation are known in the art (see, for example, Tayabali, et al. (2015), PLoS One.10(11): e0143604).
[0103] A suitable assay for assessing the virulence of a bacterial strain involves infecting a confluent monolayer of host cells or organisms, at varying dilutions, and assessing bacterial growth, production of toxins and other pathological agents by the bacteria, as well as host responses including cytokine production, neutrophil infiltration and production of serum proteins in the host animal. The assessment can be made for a given strain by comparison with a reference bacterium, for example, to establish whether the test bacterium is more infectious that the reference bacterium.
[0104] By "reduce or inhibit" is meant the ability to cause an overall decrease preferably of 20% or greater, more preferably of 50% or greater, and most preferably of 75%, 85%, 90%, 95%, or greater. Reduce or inhibit can refer to the symptoms of the disorder being treated.
[0105] Features of the invention will now be discussed with reference to the following non-limiting description and examples. B. Detailed Description
[0106] An individual’s immune response to an antigen (e.g., the activation of cell mediated response due to activation of Th17 cells or antibodies to colonizing organisms) will often be varied depending on the pathogenicity of the invading organism and the strength of an individual’s immune response at the mucosal surface that the pathogen infects.
[0107] The present invention seeks to enhance the health and wellness of a normal individual by increasing the strength of a normal individual’s immune response at the mucosal surface. This is achieved by driving or priming the normal individual’s cell mediated immune response by stimulation of the individual’s Peyer’s patches, therein activating a Th17 response in the individual. Activation of a Th17 response increases neutrophils, phagocytosis and influences a raft of cytokine responses including interferon levels. In addition, activation of a Th17 response down regulates an individual’s regulatory T cell response in the mucosa which further drives theimmune response. This response causes a shift in the balance between activation (Th17) and down regulation (Treg cells) of the immune modulators.
[0108] Thus, the invention draws on the use of specific immune enhancers, which when administered to one mucosal surface in a normal individual, enhance a Th17 cell response in said individual, activating a cell mediated immune response at the same or a different mucosal site in the individual therein priming the same or a different mucosal site in that individual creating a trained innate immunity.
[0109] Thus, in a first aspect, the invention provides a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual an immunologically stimulatory preparation of a Haemophilus influenzae strain, preferably NTHi strain, at a dose range of from about 108to about 1015killed cells prepared for administration as an oral or nasal dosage. Preferably, the immunologically stimulatory preparation is administered as a daily dose (which might be prepared and presented as multiple dosage forms leading to a delivered dose range of from about 108to about 1015killed cells) on at least 2 consecutive days at least two weeks before measuring the individual’s health and wellness or two weeks before the individual is exposed to a bacterial or viral infection of the mucosa.
[0110] The method of the first aspect of the invention relies upon a health and wellness enhancing NTHi preparation that activates or enhances an individual’s native mucosal immune system in the absence of a bacterial or viral challenge (i.e. it provides an immunologically stimulatory preparation). It is speculated by the inventor that the immunological stimulatory affects are attributed to enhancing or priming of the cell mediated immune response, therein boosting the immune system ability to protect against subsequent infections in the mucosa, such as lung and gut. By priming an individual’s immune system in this manner, the inventor can improve the health and wellness of an individual.
[0111] In this respect the health and wellness of an individual can be established by measuring an improvement in an individual’s immune system such as by measuringthe elevation or reduction of markers of an individual’s cell mediated immune system. Preferably this is achieved by measuring an elevation in the levels of GM-CSF and or a reduction in IL-10 levels.
[0112] Preferably, GM-CSF levels are elevated by about 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8 or 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.97, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9.0, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, 9.9, 10, 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 11, 11.1, 11.2, 11.3, 11.4, 11.5, 11.6, 11.7, 11.8, 11.9, 12.0, 12.1, 12.2, 12.3, 12.4, 12.5, 12.6, 12.7, 12.8, 12.9, 13, 13.1, 13.2, 13.3, 13.4, 13.5, 13.6, 13.7, 13.8, 13.9, 14, 14.1, 14.2, 14.3, 14.4, 14.5, 14.6, 14.7, 14.8, 14.9, 15.0, 15.1, 15.2, 15.3, 15.4, 15.5, 15.6, 15.7, 15.8 or 15.9 pg / mL. Elevation of serum GM-CSF levels can be determined by measuring an individual at one time point and comparing that data point to a subsequently determined serum GM-CSF level.
[0113] Alternatively or in addition, there is a reduction in serum IL-10 levels by greater than 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8 or 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5 pg / mL. A decline in serum IL-10 levels can be determined by measuring an individual at one time point and comparing that data point to a subsequently determined serum IL-10 level.
[0114] In one preferred form of the invention the immunological stimulatory preparation or formulation is administered as one dosage form / day for at least two consecutive days. In this preferred form of the invention the immunological stimulatory preparation or formulation is prepared as a single dosage for nasal or oral administration where the dosage contains about 108to about 1015killed NTHi cells.
[0115] In a second preferred form of the invention the immunological stimulatory preparation or formulation is administered as multiple dosage forms / day for at least two consecutive days. Where multiple tablets are administered in a dosing regimenthe total daily dose will be at least 108cells / day. Preferably, where multiple dosage forms are administered per day the individual will take one dosage form in the morning and one dosage form 6 to 18 hours later (preferably 12 hours later). In this preferred form of the invention each immunological stimulatory preparation is prepared as a single dosage for nasal or oral administration where the dosage contains about 108to about 1015killed NTHi cells. According to this form of the invention the individual may take one table containing about 108to about 1015killed NTHi cells in the morning and a second tablet in the evening. As the invention
[0116] In the above preferred forms of the invention the is administered immunological stimulatory preparation or formulation is administered in a dosage regimen that requires the individual to take one or more tablets per day for at least two consecutive days. In a preferred form of the invention the individual will take one or more tablets per day for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16 ,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 ,37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 consecutive days. Alternatively, the individual can take the immunological stimulatory preparation or formulation every 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11thor 12thday. Preferably the tablets are taken either every day or every 2nd, 3rd, or 4thday.
[0117] As noted above, the individual needs to generate immune resilience within their mucosa prior to becoming exposed to a bacterial or viral infection of the mucosa. Preferably the individual will take the immunological stimulatory preparation or formulation at least 5 days before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa. More preferably the individual will take the immunological stimulatory preparation or formulation at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16 ,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 ,37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 days before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa. Ideally the individual will take the immunological stimulatory preparation or formulation at least 1 month before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa.
[0118] Thus, the formulation of the invention provides a challenge to the subject mucosal immunity with at least the composition of the invention which primes at least the subject’s cell mediated immunity in the mucosa prior to a challenge by, for example a bacterial or viral attack on the subject.
[0119] This aspect of the invention also incorporates the use of an immunologically stimulatory preparation of a Haemophilus influenzae strain, preferably NTHi strain, for the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0120] In an embodiment of the first aspect of the invention, the formulation of the invention is adapted for oral delivery to a subject such that ingestion of the formulation leads to activation of a subject’s Peyer’s patches in the wall of the gut. From there, Th17 cells travel via the CMIS to the bronchus mucosa in the subject. There they secrete (1) gamma interferon which is a potent anti-viral agent, and (2) IL-17 which recruits and activates neutrophils and macrophages into the bronchus lumen, to phagocytose and destroy bacteria.
[0121] Activation of trained innate immunity with the formulation of the invention results in an increase in GM CSF, which triggers trained innate immunity by influencing the action of IL-1 at the cytokines site of action in the mucosa.
[0122] According to the invention, the immune enhancer of a subject’s common mucosal immunological system (CMIS) is a Haemophilus influenzae strain, preferably a NTHi strain, that is preferably alive and viable or dead or attenuated or non-viable or inactivated or a mixture of these different states. Preferably, a substantial portion of the Haemophilus influenzae strain, preferably a NTHi strain, in the immune enhancer are inactivated, attenuated or non-viable or a mixture of these viability states. Most preferably, a substantial portion of the Haemophilus influenzae strain, preferably a NTHi strain, are non-viable, dead bacteria and are present in the form of a multiplicity of whole bacterial cells.
[0123] In a preferred form, the NTHi preparation used in the invention is a bacterium that is alive and viable, dead, attenuated or non-viable or inactivated or amixture of these different states. Preferably, a substantial portion of the bacterium in the preparation are inactivated, attenuated or non-viable or a mixture of these viability states. More preferably, a substantial portion of the bacterium in the preparation are non-viable, dead bacteria. Most preferably, the NTHi preparation is an attenuated or non-viable or inactivated NTHi strain, such as HI-164 or a strain similar to HI-164 or NTHi-289 (also known as ARC-1).
[0124] Where the NTHi strain selected is HI-164 or is a similar strain, the strain will be characterized by a combination of any (e.g., two, three, four, five, six or all) of the following characteristics: a. Lacks a capsule gene; b. Is biotype I; c. Lacks a beta-lactamase gene; d. Grows aerobically; e. Is capable of eliciting a mucosal Haemophilus influenzae-specific IgA response, as reflected by an at least 10%, at least 20%, at least 50%, at least 70%, at least 100%, or other statistically significant increase in Haemophilus influenzae-specific IgA in the saliva; f. Is capable of stimulating Haemophilus influenzae-specific T cells in Peyer's patches, as reflected by an at least 10%, at least 20%, at least 50%, at least 70%, at least 100%, or other statistically significant increase in lymphokine production by T-cells from Peyer's patches in response to exposure to Haemophilus influenzae); g. Encodes an outer membrane protein 2 that displays at least 90%, at least 95%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity with the outer membrane 2 protein of NTHi-164; h. Encodes an outer membrane protein 26 that displays at least 90%, at least 95%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity with the outer membrane 26 protein of NTHi-164; i. Expresses an outer membrane protein 2 that runs as a doublet on single dimensional polyacrylamide gel electrophoresis; and or j. Expresses an outer membrane protein 2 that has a pi of 9.1-9.3, most preferably a pi of 9.2.
[0125] Where the NTHi strain selected is NTHi-289, the strain will be characterized by a combination of any (e.g., two, three, four, five, six or all) of the following characteristics: a. Lacks a capsule gene; b. Is biotype I; c. Lacks a beta-lactamase gene; d. Grows aerobically; e. The dominant cell phagocytosis bacteria are macrophages; f. Is capable of eliciting a mucosal Haemophilus influenzae-specific IgA response, as reflected by an at least 10%, at least 20%, at least 50%, at least 70%, at least 100%, or other statistically significant increase in Haemophilus influenzae-specific IgA in the saliva; g. Is capable of stimulating Haemophilus influenzae-specific T cells in Peyer's patches, as reflected by an at least 10%, at least 20%, at least 50%, at least 70%, at least 100%, or other statistically significant increase in lymphokine production by T-cells from Peyer's patches in response to exposure to Haemophilus influenzae); h. Encodes an outer membrane protein 2 that displays at least 90%, at least 95%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity with the outer membrane 2 protein of NTHi-289; i. Encodes an outer membrane protein 26 that displays at least 90%, at least 95%, at least 98%, at least 99%, at least 99.5%, or 100% sequence identity with the outer membrane 26 protein of NTHi-289; j. Expresses an outer membrane protein 2 that runs as a doublet on single dimensional polyacrylamide gel electrophoresis; and or k. Expresses an outer membrane protein 2 that has a pi of 9.1-9.3, most preferably a pi of 9.2.
[0126] Where the NTHi strain selected is NTHi-289 or is a similar strain, the strain will be characterized by the requirement for ‘X’ and ‘V’ factors; biochemically, using the api NH kit (bioMeÂrieux, Marcy l'Etoile, France); and by restriction fragment length polymorphism analysis (RFLP). All NTHi-289 were grown overnight at 37°C in 5% CO2on chocolate blood agar (CBA) comprising brain heart infusion agar (Oxoid,Hampshire, UK) supplemented with partially lysed 10% defibrinated horse blood (Amadeus International, Brooklyn, Victoria, Australia).
[0127] In an alternate form of the invention, the NTHi strain is not HI-164, rather the Haemophilus influenzae strain is selected from one of the Haemophilus influenzae serotypes a, b, c, d, e, and f. Preferably the preparation is prepared from H. influenzae type b isolates selected from Kilian’s biotypes I, II, III, or IV; there being eight biotypes in that classification. In an illustration of the invention the Haemophilus influenzae is selected from H. influenzae strains NTHi3219C, NTHi3224A, NTHi12, NTHi44, NTHi67, 1054MEE, 1729MEE, 1728MEE, 1885MEE, 1060MEE, RdKW20, 214NP, 1236MEE, 1714MEE, 1128MEE, 3224A, RdKW20, 86-028NP, R2846, R2866, 3655, PittAA, PittEE, PittHH, PittII, R3021, 22.4-21, 3185A, 3221B, 3219C, 3185, 3241A, 038144S1, 810956, 821246, 840645, 902550Z19, A920030, 901905U, A920029, A930105, A840177, A860514, A950014, 306543X4, A930105, 901905U, A920030, 3221B, 27W116791N, N218, N163, N162, N120, N107, N92, N91, D58PG, D219PG, D204CD, D211PG, D211PD, D201PG, D201PD, D198PG, D198PD, D195PD, D189PG, D189PD, D129CG, D124PG, D124PD, D58PG, D124CG, D330D, BS433, BS432, BS430, 1714, or 1128.
[0128] Preferably the Haemophilus influenzae strain used in the formulation is an NTHi strain such as NTHi12, NTHi44, NTHi67, NTHi164, NTHi289, NTHi3219C, or NTHi3224A.
[0129] An immunologically effective amount of whole killed cell will typically be in a range of from about 108to about 1015killed cells, more preferably from about 109to about 1013killed cells, and most preferably about 1010to about 1012killed cells. Examples of immunologically effective amount of whole killed cell will typically be 108, 109, 1010, 1011, 1012, 1013, 1014, 1015, killed cells.
[0130] In addition, the inventor has revealed that where a formulation comprising Haemophilus influenzae preferably NTHi is combined with vitamin A and or vitamin D either alone or in combination with one or more other vitamins selected from vitamin C or Z, the formulation provides enhanced means to improve the health (e.g. immunological health) or wellness of the individual.
[0131] In a second aspect, the invention provides a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof, prepared for administration as an oral or nasal dosage.
[0132] This aspect of the invention also provides a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain, prepared for administration as an oral or nasal dosage where the dosage contains about 108to about 1015killed NTHi cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof.
[0133] According to the invention, the immune health and wellness enhancing formulation of the invention includes a therapeutically effective amount of vitamin A or a derivative thereof.
[0134] As used herein vitamin A derivatives (retinol), include retinoic acid, as well as retinyl acetate, retinyl linoleate, retinyl palmitate, petinyl proprionate, retinal, tretinoin (all-trans retinoic acid (ATRA)), isotretinoin, alitretinoin, etretinate and its metabolite acitretin, adapalene, bexarotene, and tazarotene, and trifarotene.
[0135] Preferably, vitamin A or an oral derivative of vitamin A is used in the formulation of the invention. Most preferably vitamin A will be used in the formulation.
[0136] An effective amount of Vitamin A or its derivative will be in a dose of 400 to 16000 IU / day, preferably Vitamin A or its derivative is present in an amount of 400 to 15000 IU / day. For example Vitamin A or its derivative is present in an amount of 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4000, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5000, 5100, 5150, 5200, 5250, 5300, 5350, 5400, 5450, 5500, 5550, 5600, 5650, 5700, 5750, 5800, 5850, 5900, 5950, 6000, 6100, 6150, 6200, 6250, 6300, 6350, 6400, 6450, 6500, 6550, 6600, 6650, 6700, 6750, 6800, 6850, 6900, 6950, 7000, 7000, 7100, 7150, 7200, 7250, 7300, 7350, 7400, 7450, 7500, 7550, 7600, 7650, 7700, 7750, 7800, 7850, 7900, 7950, 8000, 8100, 8150, 8200, 8250, 8300, 8350, 8400, 8450, 8500, 8550, 8600, 8650, 8700, 8750, 8800, 8850, 8900, 8950, 9000, 9100, 9150, 9200, 9250, 9300, 9350, 9400, 9450, 9500, 9550, 9600, 9650, 9700, 9750, 9800, 9850, 9900, 9950, 10000, 11000, 11100, 11150, 11200, 11250, 11300, 11350, 11400, 11450, 11500, 11550, 11600, 11650, 11700, 11750, 11800, 11850, 11900, 11950, 12000, 12100, 12150, 12200, 12250, 12300, 12350, 12400, 12450, 12500, 12550, 12600, 12650, 12700, 12750, 12800, 12850, 12900, 12950, 13000, 13100, 13150, 13200, 13250, 13300, 13350, 13400, 13450, 13500, 13550, 13600, 13650, 13700, 13750, 13800, 13850, 13900, 13950, 14000, 14000, 14100, 14150, 14200, 14250, 14300, 14350, 14400, 14450, 14500, 14550, 14600, 14650, 14700, 14750, 14800, 14850, 14900, 14950, 15000, 15100, 15150, 15200, 15250, 15300, 15350, 15400, 15450, 15500, 15550, 15600, 15650, 15700, 15750, 15800, 15850, 15900, 15950 or 16000 IU / day are used.
[0137] In one preferred form of the invention the vitamin A immunological stimulatory preparation or formulation of the invention is administered as one dosage form / day for at least two consecutive days. In this preferred form of the invention the vitamin A immunological stimulatory preparation or formulation is prepared as a single dosage for nasal or oral administration where the dosage contains about 108to about 1015killed NTHi cells.
[0138] In a second preferred form of the invention the vitamin A immunological stimulatory preparation or formulation of the invention is administered as multiple dosage forms / day for at least two consecutive days. Where multiple tablets are administered in a dosing regimen the total daily dose will be at least 108cells / day. Preferably, where multiple dosage forms are administered per day the individual will take one dosage form in the morning and one dosage form 6 to 18 hours later (preferably 12 hours later). In this preferred form of the invention each vitamin A immunological stimulatory preparation is prepared as a single dosage for nasal or oral administration where the dosage contains about 108to about 1015killed NTHi cells. According to this form of the invention the individual may take one table containing about 108to about 1015killed NTHi cells in the morning and a second tablet in the evening. As the invention
[0139] In the above preferred forms of the invention the is administered vitamin A immunological stimulatory preparation or formulation of the invention is administered in a dosage regimen that requires the individual to take one or more tablets per day for at least two consecutive days. In a preferred form of the invention the individual will take one or more tablets per day for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16 ,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 ,37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 consecutive days. Alternatively, the individual can take the vitamin A immunological stimulatory preparation or formulation every 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11thor 12thday. Preferably the tablets are taken either every day or every 2nd, 3rd, or 4thday.
[0140] As noted above, the individual needs to generate immune resilience within their mucosa prior to becoming exposed to a bacterial or viral infection of the mucosa. Preferably the individual will take the vitamin A immunological stimulatory preparation or formulation of the invention at least 5 days before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa. More preferably the individual will take the vitamin A immunological stimulatory preparation or formulation at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16 ,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 ,37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60days before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa. Ideally the individual will take the vitamin A immunological stimulatory preparation or formulation of the invention at least 1 month before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa.
[0141] According to the invention, the immune health and wellness enhancing formulation of the invention can optionally include a therapeutically effective amount of vitamin D or a derivative thereof.
[0142] As used herein vitamin D derivatives include calcitriol, calcipotriol, ergocalciferol, cholecalciferol, alfacalcidol, dihydrotachysterol, sitocalciferol or paricalcitol
[0143] Preferably, vitamin D or an oral derivative of vitamin D is used in the formulation of the invention. Most preferably vitamin D will be used in the formulation.
[0144] An effective amount of Vitamin D or its derivative will be in a dose of 400 to 60000 IU / day, preferably Vitamin D or its derivative is present in an amount of 10000 to 50000 IU / day. For example, Vitamin D or its derivative is present in an amount of 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1150, 1200, 1250, 1300, 1350, 1400, 1450, 1500, 1550, 1600, 1650, 1700, 1750, 1800, 1850, 1900, 1950, 2000, 2100, 2150, 2200, 2250, 2300, 2350, 2400, 2450, 2500, 2550, 2600, 2650, 2700, 2750, 2800, 2850, 2900, 2950, 3000, 3100, 3150, 3200, 3250, 3300, 3350, 3400, 3450, 3500, 3550, 3600, 3650, 3700, 3750, 3800, 3850, 3900, 3950, 4000, 4100, 4150, 4200, 4250, 4300, 4350, 4400, 4450, 4500, 4550, 4600, 4650, 4700, 4750, 4800, 4850, 4900, 4950, 5000, 5100, 5150, 5200, 5250, 5300, 5350, 5400, 5450, 5500, 5550, 5600, 5650, 5700, 5750, 5800, 5850, 5900, 5950, 6000, 6100, 6150, 6200, 6250, 6300, 6350, 6400, 6450, 6500, 6550, 6600, 6650, 6700, 6750, 6800, 6850, 6900, 6950, 7000, 7000, 7100, 7150, 7200, 7250, 7300, 7350, 7400, 7450, 7500, 7550, 7600, 7650, 7700, 7750, 7800, 7850, 7900, 7950, 8000, 8100, 8150, 8200, 8250, 8300, 8350, 8400, 8450, 8500, 8550, 8600, 8650, 8700, 8750, 8800, 8850, 8900, 8950, 9000, 9100, 9150, 9200, 9250, 9300, 9350, 9400, 9450, 9500, 9550, 9600, 9650, 9700, 9750, 9800, 9850, 9900, 9950, 10000, 15000, 20000, 25000, 30000, 35000, 40000, 45000, 50000, 55000 or 60000 IU / day.
[0145] In a further embodiment of the second aspect of the invention resides in the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and in the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0146] In a further embodiment of the second aspect of the invention resides in the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and in the manufacture of a medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0147] In yet another embodiment of the second aspect the invention resides in an immune health and wellness enhancing formulation for use in a normal individual, said formulation comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof, wherein the formulation is prepared for administration as an oral or nasal dosage.
[0148] In an alternate form of the above embodiment the invention resides in an immune health and wellness enhancing formulation for use in a normal individual, said formulation comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal dosage; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof.
[0149] In one preferred form of the invention the vitamin A and or D immunological stimulatory preparation or formulation of the invention is administered as one dosage form / day for at least two consecutive days. In this preferred form of the invention the vitamin A and or D immunological stimulatory preparation or formulation of the invention is prepared as a single dosage for nasal or oral administration where the dosage contains about 108to about 1015killed NTHi cells.
[0150] In a second preferred form of the invention the vitamin A and or D immunological stimulatory preparation or formulation of the invention is administered as multiple dosage forms / day for at least two consecutive days. Where multiple tablets are administered in a dosing regimen the total daily dose will be at least 108cells / day. Preferably, where multiple dosage forms are administered per day the individual will take one dosage form in the morning and one dosage form 6 to 18 hours later (preferably 12 hours later). In this preferred form of the invention each vitamin A and or D immunological stimulatory preparation is prepared as a single dosage for nasal or oral administration where the dosage contains about 108to about 1015killed NTHi cells. According to this form of the invention the individual may take one table containing about 108to about 1015killed NTHi cells in the morning and a second tablet in the evening. As the invention
[0151] In the above preferred forms of the invention the is administered vitamin A and or D immunological stimulatory preparation or formulation is administered in a dosage regimen that requires the individual to take one or more tablets per day for at least two consecutive days. In a preferred form of the invention the individual will take one or more tablets per day for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16 ,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 ,37, 38,39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 consecutive days. Alternatively, the individual can take the vitamin A and or D immunological stimulatory preparation or formulation every 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11thor 12thday. Preferably the tablets are taken either every day or every 2nd, 3rd, or 4thday.
[0152] As noted above, the individual needs to generate immune resilience within their mucosa prior to becoming exposed to a bacterial or viral infection of the mucosa. Preferably the individual will take the vitamin A and or D immunological stimulatory preparation or formulation of the invention at least 5 days before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa. More preferably the individual will take the vitamin A and or D immunological stimulatory preparation or formulation of the invention at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16 ,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 ,37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 days before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa. Ideally the individual will take the vitamin A and or D immunological stimulatory preparation or formulation of the invention at least 1 month before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa.
[0153] In addition to Vitamin A and or D the formulations described above may optionally include a therapeutically effective amount of zinc, or a zinc ionophore (such as a polyphenol), which aides in the prevention of mucosal diseases, conditions or disorders associated with a subject’s mucosa (including, without limitation, respiratory, digestive, and urogenital tracts).
[0154] According to a third aspect of the invention there is provided a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition ordisorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol),
[0155] Where the invention includes a therapeutically effective amount of zinc, or a zinc ionophore the zinc is preferably provided as a polyphenol, quercetin, epigallocatechin-gallate, chloroquine and hydroxychloroquine, such as clioquinol or bromelain.
[0156] An effective amount of zinc, or a zinc ionophore will be in a dose of 5 to 500 mg / day. More preferably zinc is present in a dose of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500 mg / day.
[0157] According to an alternate form of the third aspect of the invention there is provided a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; andc. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), wherein the formulation is prepared for administration as an oral or nasal dosage.
[0158] In an embodiment of the third aspect, the invention resides in the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), in the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0159] In an alternate embodiment of the third aspect, the invention resides in the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), in the manufacture of a medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0160] In another embodiment of the third aspect of the invention, the formulation includes zinc, or a zinc ionophore (such as a polyphenol), which enhances the benefitor effect of the formulation on an individual’s mucosal immune system. According to this embodiment the formulation comprises: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
[0161] In yet another embodiment, the immune health and wellness enhancing formulation comprises: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), wherein the formulation is prepared for administration as an oral or nasal dosage.
[0162] In one preferred form of the invention the vitamin A, D and Zn immunological stimulatory preparation or formulation of the invention is administered as one dosage form / day for at least two consecutive days. In this preferred form of the invention the vitamin A immunological stimulatory preparation or formulation is prepared as a single dosage for nasal or oral administration where the dosage contains about 108to about 1015killed NTHi cells.
[0163] In a second preferred form of the invention the vitamin A, D and Zn immunological stimulatory preparation or formulation of the invention is administered as multiple dosage forms / day for at least two consecutive days. Where multiple tablets are administered in a dosing regimen the total daily dose will be at least 108cells / day. Preferably, where multiple dosage forms are administered per day the individual will take one dosage form in the morning and one dosage form 6 to 18 hours later (preferably 12 hours later). In this preferred form of the invention each vitamin Aimmunological stimulatory preparation is prepared as a single dosage for nasal or oral administration where the dosage contains about 108to about 1015killed NTHi cells. According to this form of the invention the individual may take one table containing about 108to about 1015killed NTHi cells in the morning and a second tablet in the evening.
[0164] In the above preferred forms of the invention the is administered vitamin A, D and Zn immunological stimulatory preparation or formulation of the invention is administered in a dosage regimen that requires the individual to take one or more tablets per day for at least two consecutive days. In a preferred form of the invention the individual will take one or more tablets per day for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16 ,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 ,37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 consecutive days. Alternatively, the individual can take the vitamin A, D and Zn immunological stimulatory preparation or formulation every 2nd, 3rd, 4th, 5th, 6th, 7th, 8th, 9th, 10th, 11thor 12thday. Preferably the tablets are taken either every day or every 2nd, 3rd, or 4thday.
[0165] As noted above, the individual needs to generate immune resilience within their mucosa prior to becoming exposed to a bacterial or viral infection of the mucosa. Preferably the individual will take the vitamin A, D and Zn immunological stimulatory preparation or formulation of the invention at least 5 days before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa. More preferably the individual will take the vitamin A, D and Zn immunological stimulatory preparation or formulation at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16 ,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 ,37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 days before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa. Ideally the individual will take the vitamin A, D and Zn immunological stimulatory preparation or formulation of the invention at least 1 month before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa.
[0166] By improving an individual’s health and wellness using a formulation as described herein, an individual’s mucosal immune system can be primed for resisting subsequent infection presenting the individual with greater capacity to either (a) resist a disease, condition or disorder of bacterial or viral origin, or (b) to ameliorate the effect of a bacterial or viral challenge to the individual.
[0167] In a fourth aspect of the invention, the invention resides in a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
[0168] In an alternate form of the fourth aspect of the invention, the invention resides in a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), wherein the formulation is prepared for administration as an oral or nasal dosage.
[0169] According to the fourth aspect of the invention, the invention includes a therapeutically effective amount of Vitamin C (L-ascorbic acid) or derivative thereof such as Sodium Ascorbyl Phosphate (SAP), Magnesium Ascorbyl Phosphate (MAP), Ascorbyl Palmitate (AA-PAL), Ascorbyl Tetra-Isopalmitate (VC-IP), Ascorbyl Glucoside (AA-2G), Ascorbyl 2-Phosphate 6-Palmitate (APPS), or 3-O-Ethyl Ascorbate (EAC).
[0170] Preferably, vitamin C or an oral derivative of vitamin C is used in the formulation of the invention. Most preferably vitamin C will be used in the formulation.
[0171] An effective amount of vitamin C, or a derivative thereof will be in a dose of 5 to 1000 mg / day. More preferably vitamin C is present in a dose of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990, 995 or 1000 mg / day.
[0172] The above embodiment of the fourth aspect of the invention also incorporates the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol),in the manufacture of a medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0173] The above embodiment of the second aspect of the invention also incorporates the use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), for the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
[0174] According to the fourth aspect of the invention, the formulation comprises: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
[0175] According to yet another embodiment, the fourth aspect of the invention includes a formulation comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; andb. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
[0176] In one preferred form of the invention the vitamin A, D, C and Zn immunological stimulatory preparation or formulation of the invention is administered as one dosage form / day for at least two consecutive days. In this preferred form of the invention the vitamin A immunological stimulatory preparation or formulation is prepared as a single dosage for nasal or oral administration where the dosage contains about 108to about 1015killed NTHi cells.
[0177] In a second preferred form of the invention the vitamin A, D, C and Zn immunological stimulatory preparation or formulation of the invention is administered as multiple dosage forms / day for at least two consecutive days. Where multiple tablets are administered in a dosing regimen the total daily dose will be at least 108cells / day. Preferably, where multiple dosage forms are administered per day the individual will take one dosage form in the morning and one dosage form 6 to 18 hours later (preferably 12 hours later). In this preferred form of the invention each vitamin A immunological stimulatory preparation is prepared as a single dosage for nasal or oral administration where the dosage contains about 108to about 1015killed NTHi cells. According to this form of the invention the individual may take one table containing about 108to about 1015killed NTHi cells in the morning and a second tablet in the evening.
[0178] In the above preferred forms of the invention the is administered vitamin A, D, C and Zn immunological stimulatory preparation or formulation of the invention is administered in a dosage regimen that requires the individual to take one or more tablets per day for at least two consecutive days. In a preferred form of the invention the individual will take one or more tablets per day for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16 ,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 ,37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 consecutive days. Alternatively, the individual can take the vitamin A, D, C and Zn immunological stimulatory preparation or formulation every 2nd, 3rd, 4th,5th, 6th, 7th, 8th, 9th, 10th, 11thor 12thday. Preferably the tablets are taken either every day or every 2nd, 3rd, or 4thday.
[0179] As noted above, the individual needs to generate immune resilience within their mucosa prior to becoming exposed to a bacterial or viral infection of the mucosa. Preferably the individual will take the vitamin A, D, C and Zn immunological stimulatory preparation or formulation of the invention at least 5 days before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa. More preferably the individual will take the vitamin A, D, C and Zn immunological stimulatory preparation or formulation at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16 ,17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 ,37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60 days before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa. Ideally the individual will take the vitamin A, D, C and Zn immunological stimulatory preparation or formulation of the invention at least 1 month before measuring the individual’s health and wellness or before the individual is exposed to a bacterial or viral infection of the mucosa.
[0180] In a fifth aspect, the invention provides a method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual an amount of the formulation described in the second, third or fourth aspects of the invention or their embodiments, sufficient to stimulate an individual’s cell mediated immune system. Stimulation of an individual’s cell mediated immune system is preferably measured by measuring variation in IL-1, TNF, IL-6 inflammatory cytokines, and chemokine for neutrophils (MIP-2 equivalent to IL-8 - chemokine for neutrophils; and MCP-1 - chemokine for macrophages). Generally, one or more of these cytokines or chemokines will be elevated. Their elevation is reflective of an active inflammatory process underpinning cellular response to live bacteria.Assays for both lung tissue and the Bronchial Washings, and both protein and mRNA analyses may be used.
[0181] Preferably, the formulation delivered to the individual in pulse doses so that the individual’s mucosa is “prepared” and can then cope quickly and effectively no matter what pathogen comes its way.
[0182] Preferably, the formulation is dosed and formulated in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient (e.g. the overall health of the subject), the cause of the disorder, the severity of the symptoms, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners.
[0183] When considering the dosage of the formulation of the invention factors such as the route of administration; the severity of the condition to be treated; the nature of the formulation; the nature of the subject's illness; the subject's size, weight, surface area, age, and sex; other drugs being administered; and the judgment of the attending physician will affect the dosage requirement. Wide variations in the needed dosage are to be expected in view of the variety of immune enhancers and active agents available and the differing efficiencies of various routes of administration. Variations in dosage levels can be adjusted using standard empirical routines for optimization as is well understood in the art.
[0184] The optimum dosage of a formulation can be determined by administering different dosages to different groups of test mammals, prior to subsequently infecting the animals in each group with the microorganism and determining the dosage level required to achieve satisfactory clearance of the pathogen.
[0185] A formulation of the invention may also comprise one or more pharmaceutically acceptable carriers and / or adjuvants. Exemplary adjuvants that may be used are further detailed below. Typically, although not exclusively, the preferred formulation is non-adjuvanted. Actual methods for preparing the formulations of the invention will be known or apparent to those skilled in the art and are described inmore detail in such publications as Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pa. (1980).
[0186] Depending upon the half-lives of a formulation of the invention in a particular subject, formulations of the invention can be administered between several times per day to once a week. The methods of the present invention provide for single as well as multiple administrations, given either simultaneously or over an extended period of time. Route of administration
[0187] The formulation of the invention is manufactured for delivery based on the route of administration which includes inhalation, orally, bronchial injection, intranasally.
[0188] Preferably the formulation is manufactured for oral administration in the form of a pill, tablet, capsule, liquid, or sustained release tablet for oral administration.
[0189] In such circumstances, the formulations are produced by preparing a substantially anhydrous mixture of the components and then optionally filling uncoated capsules with the mixture and optionally coating them with an appropriate polymer mixture to achieve the desired permeability properties.
[0190] Bacterium prepared according to the invention are desirably prepared for oral administration such as in the form of a syrup, gel, semi-solid, capsule or tablet that comprises a therapeutically acceptable amount of the bacterium to achieve its normal therapeutic effect. For example, the syrup, capsule or tablet may contain from 0.05 to 50%, preferably from 0.1 to 25%, more preferably from 0.1 to 10% by weight of the bacterium based on the weight of the capsule contents (not including the capsule itself).
[0191] The syrup, gel, semi-solid, capsule or tablet may optionally further comprise any conventional additive used in the formulation of pharmaceutical products including, for example, antioxidants, suspending agents, fillers, diluents, disintegrants, swelling agents, viscosity regulators, plasticisers and acidity regulators (particularly those adjusting the intestinal milieu to between 7 and 7.5).
[0192] Where the intended site of action of the formulation of the invention is the intestine, it is preferable that the formulation is enclosed within an enteric coating which can withstand the stomach, so that the components of the formulation remain together, undiluted and in close association until they reach the tissues of the small intestine or colon. Such formulations will suitably be anhydrous. Formulations in liquid form will suitably be administered as enteric-coated capsules, while solid formulations may be administered either within enteric-coated capsules, or in tablet form.
[0193] The enteric coating is chosen appropriately to withstand the natural condition of the stomach and to become permeable at the desired location in the intestine. This is preferably determined by the pH conditions which modulate along the length of the intestine. Where the site of action is the small intestine, it is preferred that the enteric coating becomes permeable and releases its contents at a pH from 3 to 7, preferably from 5.5 to 7, more preferably from 5.5 to 6.5. Where the intended site of action is the colon, it is preferred that the enteric coating becomes permeable and releases its contents at a pH of 6.8 or above.
[0194] Suitable enteric coatings are well known in the art and can readily be made by the person skilled in the art based on their knowledge and the available literature supporting the products.
[0195] Where the formulation is desired for oral administration the formulation may additionally include at least a pharmaceutically acceptable additive (such as a diluent, carrier, adjunct, excipient or non-toxic, non-therapeutic, non-immunogenic stabilizers and the like).
[0196] Any diluent used in the formulation of the invention is preferably selected so as not to unduly affect the biological activity of the bacterium. Examples of such diluents which are especially useful for injectable formulations are water, the various saline, organic or inorganic salt solutions, Ringer's solution, dextrose solution, and Hank's solution.
[0197] Other agents may be employed in the formulation for a variety of purposes. For example, buffering agents, preservatives, co-solvents, surfactants, oils, humectants, emollients, chelating agents, stabilizers or antioxidants may be employed. Water soluble preservatives which may be employed include, but are not limited to,benzalkonium chloride, chlorobutanol, thimerosal, sodium bisulfate, phenylmercuric acetate, phenylmercuric nitrate, ethyl alcohol, methylparaben, polyvinyl alcohol, benzyl alcohol and phenylethyl alcohol. A surfactant may be Tween 80. Other vehicles that may be used include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose, purified water, etc. Tonicity adjustors may be included, for example, sodium chloride, potassium chloride, mannitol, glycerin, etc. Antioxidants include, but are not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, butylated hydroxytoluene, etc. The indications, effective doses, formulations, contraindications, vendors etc., of the compounds in the formulation are available or are known to one skilled in the art.
[0198] The above agents may be present in individual amounts of from about 0.001 to about 5% by weight and preferably about 0.01% to about 2%. Suitable water- soluble buffering agents that may be employed are sodium carbonate, sodium borate, sodium phosphate, sodium acetate, sodium bicarbonate, etc., as approved by the US FDA for the desired route of administration. These agents may be present in amounts sufficient to maintain a pH of the system of between about 2 to about 9 and preferably about 4 to about 8. As such the buffering agent may be as much as about 5% on a weight to weight basis of the total formulation. Electrolytes such as, but not limited to, sodium chloride and potassium chloride may also be included in the formulation.
[0199] Moreover, the formulation may be formulated as a slow release formulation, with a carrier formulation such as microspheres, microcapsules, liposomes, etc., as an intravenous solution or suspension, or in an intraocular injection, as known to one skilled in the art. A time-release drug delivery system may be used to sustain release of the composition over a period of time.
[0200] Where the formulation is in a sustained release form it can be in the form of a vehicle, such as a micro- or macro-capsule or matrix of biocompatible polymers such as polycaprolactone, polyglycolic acid, polylactic acid, polyanhydrides, polylactide-co-glycolides, polyamino acids, polyethylene oxide, acrylic terminated polyethylene oxide, polyamides, polyethylenes, polyacrylonitriles, polyphosphazenes, poly(ortho esters), sucrose acetate isobutyrate (SAIB), and other polymers such as those disclosed in U.S. Patent Nos. 6,667,371; 6,613,355; 6,596,296; 6,413,536;5,968,543; 4,079,038; 4,093,709; 4,131,648; 4,138,344; 4,180,646; 4,304,767; 4,946,931, each of which is expressly incorporated by reference herein in its entirety, or lipids that may be formulated as microspheres or liposomes. Delayed or extended- release properties may also be provided through various formulations of the composition (such as coated or uncoated microspheres, coated or uncoated capsules, lipid or polymer components, unilamellar or multilamellar structures, and combinations of the above, etc.).
[0201] According to the invention the bacterium may be prepared as a mixture which is either in the form of a solution or a microparticulate dispersion. That is, the bacterium and / or the second active agent can be incorporated into the formulation either in the form of a solution or as a microparticulate dispersion.
[0202] In an alternate form, the formulation is suitable for administration via the nasal palate or the lungs.
[0203] Where the intended site of action is the nasal mucosa, the formulation is in the form of an aqueous solution or as a dry powder, which can be administered as a spray.
[0204] Administration of the formulation can be single or multiple (e.g., 2, 3, 6, 8, 10, 20, 50, 100, 150, or more) doses and can continue for a period of time ranging from 2 days, 3 days, 4 days, 5 days, 6 days or 7 days or 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31. Days, to 1 month through the lifetime of the subject, more preferably 1 to 100 days, and most preferably 1 to 20 days and most preferably, until the symptoms of the infection or inflammatory disease or disorder, or symptoms thereof are reduced or removed. Method of Production
[0205] In a sixth aspect, the invention is directed to a method of preparing a formulation wherein the method including the steps of: (i) culturing live cells of a selected NTHi bacterium; (ii) inactivating the NTHI bacterium by killing the cells; and (iii) formulating the inactivated bacterium into a formulation with the other constituents of the formulation.Kits
[0206] In a seventh aspect, the invention is directed to a kit for improving an individual’s health and or wellness comprising: an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, prepared for administration as an oral or nasal therapeutic.
[0207] In an embodiment of the seventh aspect the invention is also directed to a kit for improving an individual’s health and or wellness comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. a therapeutically effective amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof.
[0208] A kit will also include instructions for employing the kit components in accordance with the methods described herein as well the use of any other reagent not included in the kit. Instructions may include variations that can be implemented. EXAMPLES
[0209] Further features of the present invention are more fully described in the following non-limiting Examples. This description is included solely for the purposes of exemplifying the present invention. It should not be understood as a restriction on the broad description of the invention as set out above. Example 1: Composition: Preparation of a vaccine containing H. influenzae
[0210] Hemophilus influenzae type B No. 7279 (NIH 1946) was cultured in suspension in a medium of casamino acids essentially as described by P. Anderson, J. Pritt and D. H. Smith, Infection and Immunity 13, 581-589 (1976). The medium consisted of 1% Casamino Acids (Difco) 0.5% yeast extract (Difco), 0.05 M sodium phosphate buffer and 0.5% glucose, supplemented with horse blood (dilution (1:1000) and 1 µg / ml nicotinamide ade-nine dinucleotide (Sigma). This yielded approximately 1.3 X 109colony-forming units per ml (CPU / ml) and 8 X 1013total viable cells. Similarresults were obtained in Eugon broth in place of casamino acids (7 X 108CPU / ml). Cultures were shown to be pure by testing with an api 20B identification kit as well as by microscopic examination. The organism is notoriously pleomorphic in liquid culture.
[0211] Cells were harvested by continuous centrifugation, washed three times using physiological saline and inac-tivated by resuspending in 0.5% formalin in saline at a concentration of 5 X 109CFU / ml. After 3 days, sterility was tested by inoculation into growth media and on CHB agar. No growth of any organism occurred after 7 days incubation at 36° C. Inactivated cells were lyophilized using a protective medium composed of dextran 40 / lactose. In the absence of the protective medium, extensive cell disruption was observed. All precautions were taken during lyophilization to maintain sterility of the product. The dispensing area, including the freeze-drying chamber, were fumigated. Sterile trays, jars and other equipment were used, and sterile air was introduced into the chamber at the end of the drying cycle. The weight of 8 X 1013cells lyophilized by this method amounted to 75.8g (1011cells per 0.1 g).
[0212] Tablets were prepared from the lyophilized killed Hemophilus influenzae according to the following formula: a. granulation: i. lyophilized bacteria 100 mg ii. sodium taurocholate 25 mg b. granulating agent: dry blend i. lactose 100mg ii. alcohol 95SG type F3 qs iii. maize starch 10g iv. Polyplasdone XL TM 7.5mg v. magnesium stearate 4mg
[0213] The compression weight is 246.5 mg, showing a core hardness of 5 kg (Monsanto) and a disintegration time of the core in pH 6.8 phosphate buffer of 14 minutes. The tablets are coated with a coating solution consisting of: a. cellulose acetate phthalate 12g b. propylene glycol 3gc. Tween 80 ® 1g d. alcohol abs.40ml e. iron oxide red pigment .3g f. iron oxide yellow pigment 1.2g g. acetone to 100ml The enteric coated tablet weighs 265 mg and shows a disintegration time of more than 2 hours in 0.1 N HCl and of 16 minutes in pH 6.8 phosphate buffer. Example 2: Comparison of Buccaline and the formulation of Example 1
[0214] The purpose of this example is to determine if healthy normal subjects could be protected within the “health spectrum” ie could they switch immune resistance so those meeting a virus (eg Influenza or COVID) would get tighter immune control ie less inflammation and more effective clearance of pathogen. Until this study oral NTHi studies have been in subjects with chronic airway disease. To the best of the inventor’s knowledge these studies have not been conducted on normal healthy individuals.
[0215] Healthy “normal” individuals were selected that were not suffering from a mucosal disease, condition or disorder within the respiratory, digestive, or urogenital tracts, as measured by variation in the levels of GM-CSF which is a connect molecule which triggers recruitment and phenotypic changes typical of learned immunity, measured according to the methodologies disclosed in Borriello, F et al Int J Mol Sci 20 (2019) 834.
[0216] The individuals were broken into two pools, one receiving Buccaline as per manufacturer’s instructions and a second pool that received NTHi enteric coated tablets containing 1011inactivated NTHi (Two tablets a day) produced as per Example 1.
[0217] Individuals were sampled 34 and 62 days after taking the Buccaline or NTHi enteric coated tablets. This measure was to determine immune resilience which is a measure of the efficacy of delivery of T cells from Peyer’s patches to the airway mucosa, which in turn determines how well aspirated (swallowed) microbiome, is presented to the Peyer’s patches.
[0218] In graph 1 the inventor compared antigen stimulation ratios (with NTHi antigen) for both oral NTHi and a polybacterial product – Buccaline, which contains NTHi ie the bacterial “mix” acts as an adjuvant to deliver MORE antigen reactive (specific) T cells to the bronchus mucosa: oral NTHi has a very different outcome. There is greater antigen-specific stimulation post oral NTHi, compared with the polyclonal response to the T cell mitogen PHA in those taking oral NTHi compared to the Buccaline group. The important point is that the adjuvanted NTHi in Buccaline produces disproportionate more non-specific T cells which block access of specific T cells, hence less enhanced immunity.
[0219] For example, in a study of healthy smokers (RL Clancy and ML Dunkley, 2010 Clin Exp Immunol v161(1) 127-133) 25% of normal subjects have ineffective T cell delivery, and are thus less immune resilient, and more prone to risk factors such as smoking.
[0220] When Buccaline (which is a mix of 7-8 different bacteria incl NTHi) is administered to individual it should deliver less specific T cells to the mucosa, as compared to single species oral NTHi. Yet unexpectedly, the opposite is true. These data show the most likely reason is that following Buccaline administration there is a flood of non-specific T cells mobilised from Peyer’s patches, that bind to the receptors in the lungs. Thus, there is greater competition between specific and non-specific T cells for entry into the bronchus space, with favouring of uptake of specific antigen reactive T cells following a single species product.
[0221] Thus, more specific T cells are generated from Peyer’s patches following Buccaline than seen following oral NTHi. Relevantly, the graph 1 identifies the mechanism that enables oral NTHi – a less intense stimulus - to be more effective at activating and controlling innate immunity, which in turn decreases the colonising microbiome (which works with inhaled virus to cause excess inflammation with purulent sputum etc. that we call acute bronchitis). In the second graph, the ratio of non-specific to specific T cells (the ones needed in the bronchus mucosa for restimulation to drive innate immunity) is very different. Thus, with Buccaline, and the like, the mitogenic effect of the “mix” of bacteria produces an excess T cells that do not bear receptors for NTHi which receptors are needed to be re-stimulated once theyget into the mucosa. Instead, they block receptors needed for the specific T cells to access the mucosal space. Thus, there is less clinical efficacy. Example 3: Treatment of antibiotic resistant bacteria or refractory subjects
[0222] In this example a middle-aged healthy woman is keen to prevent significant symptoms from antibiotic resistant bacteria. According to the method, the woman respiratory mucosa is checked for residual symptoms from antibiotic resistant bacteria. There were no such bacteria present.
[0223] The woman takes a daily therapy for 3 consecutive days each month of NTHi enteric coated tablets containing 1011inactivated NTHi (two tablets per day) produced as per Example 1. Example 4
[0224] In this example, the immune enhancer of the present invention is used to protect a normal individual from viral infections, such as infection due to SARS, MERS and SARS-CoV-2 (COVID-19). According to this method an immune enhancer produced according to Example 1 is administered in a dosing regimen wherein the immune enhancer primes the immune system in accordance with the teachings of the present invention which promotes mucosal immune protection.
[0225] The oral dosing regimen discussed below commences with a three month “priming” of the immune system followed by a six month “booster” dose, repeated annually.
[0226] To commence the dosing regime, an effective amount of an oral dose of NTHi is administered to a subject in need thereof on day 1 for a period of three days (that is, days 1 to 3 inclusive). The administration of the oral dose of the NTHi primes the mucosal immune response and assists in maintaining an effective innate immunity. It is considered that such priming occurs at the respiratory tract and all mucosa when NTHi is administered as the immune enhancer.
[0227] This dosing cycle is repeated for three months. After three months, the subject receives a one month booster, repeating the 28 day dosing regimen discussed above. After a further six months, the entire dosing regime is repeated.
[0228] The subject exhibits an improvement in their respiratory wellness. Example 5: Composition containing Retinol
[0229] Tablets were prepared as above except that to the granulating agent retinol palmitate at 15,000ug was added to produce a NTHi enteric coated tablets with Retinol. Example 6: Treatment of antibiotic resistant bacteria or refractory subjects
[0230] In the present study a middle-aged healthy woman is keen to prevent significant symptoms from antibiotic resistant bacteria.
[0231] The woman took a daily therapy for 3 consecutive days each month of: a. NTHi enteric coated tablets containing 1011inactivated NTHi. Two tablets a day; and b. Vit A Capsules (e.g. as retinol palmitate 15,000ug).
[0232] At annual review there were no residual symptoms from antibiotic resistant bacteria. Example 7:
[0233] The below describes one of the embodiments of the present invention which optimises the common mucosal immunological system in a subject, resulting in the protection of the mucosa of the gut and / or the air ways. The following dosage regime aims to show that it is possible to prime the immune system to protect against bacteria-driven inflammation. For example, the immunogenic composition may be used in protection against bacteria-drive airway inflammation that results from viral infections, such as infection due to SARS, MERS and SARS-CoV-2 (COVID-19). The following may be used either alone or in combination with a second active agent as described above.
[0234] The immune enhancers of the present invention, such as bacteria commonly isolated from the gut or respiratory tract, when treated and administered as an oral therapeutic formulation to a subject and when combined with Vitamin A either alone or in combination with one or more other vitamins or minerals have been usedto treat, prevent or ameliorate inflammatory diseases, conditions or disorders associated with a subject’s mucosa (including, without limitation, respiratory, digestive, and urogenital tracts).
[0235] In this example, the immune enhancer of the present invention is administered with at least one vitamin or mineral in a dosing regimen wherein the immune enhancer primes the immune system in accordance with the teachings of the present invention followed by administration of one or more vitamins or minerals (or a combination thereof) which promotes mucosal immune protection.
[0236] The oral dosing regimen discussed below commences with a three month “priming” of the immune system followed by a six month “booster” dose, repeated annually.
[0237] To commence the dosing regime, an effective amount of an oral dose of NTHi is administered to a subject in need thereof on day 1 for a period of three days (that is, days 1 to 3 inclusive). The administration of the oral dose of the NTHi primes the mucosal immune response and assists in maintaining an effective innate immunity. It is considered that such priming occurs at the respiratory tract and all mucosa when NTHi is administered as the immune enhancer.
[0238] On days 4 to 28 (inclusive) the subject receives an oral dose of at least one vitamin or mineral, preferably a combination thereof. The vitamins / minerals may be selected from Vitamin A, Vitamin D, Vitamin C, zinc and a zinc ionophore. The zinc ionophore may be selected from the group comprising: a polyphenol, such as quercetin, epigallocatechin-gallate; and a hydroxychloroquine, such as clioquinol or bromelain.
[0239] This 28 day dose cycle is repeated for three months. After three months, the subject receives a one month booster, repeating the 28 day dosing regimen discussed above. After a further six months, the entire dosing regime is repeated. Exemplified Dosing Schedule
[0240] The present regime is repeated annually. On days 1 to 3 inclusive of the first month, a dose of NTHi at 2 x1011is administered daily to a subject receivingtreatment. On days 4 to 28 (inclusive), the subject is administered Vitamin A at a dose of 10,000 units / day. Alternatively, the subject is administered a combination of vitamins and minerals in a vitamin mixture. The Vitamin A alone or the mixture of vitamins / minerals is referred to herein as the “vitamin supplement”.
[0241] In a preferred example, the vitamin mixture comprises the following: a. Vitamin A (10,000 units / day) b. Vitamin C (500 mg / day) c. Vitamin D (at least 5,000 mg / day) d. Zinc (25 to 40 mg / day); and optionally e. A zinc ionophore (in a sufficient amount to assist in the transport of the zinc cation through the plasma membrane).
[0242] In an alternate example, the vitamin mixture comprises the above and further includes one or both of: a. Quercetin (500 mg) b. Bromelain (250 mg)
[0243] Vitamin A alone or in combination, such as discussed above, is referred to as the vitamin / mineral supplement in the following.
[0244] After 28 days (first month), the subject is administered a further oral dose of the immune enhancer on days 1 to 3, inclusive (commencement of the second month), followed by the vitamin supplement on days 4 to 28, inclusive. At the end of the two months, the dosing is repeated again, commencing with the oral dose of the immune enhancer on days 1 to 3, inclusive (commencement of the third month) followed by the vitamin supplement on days 4 to 28, inclusive. Six months from the commencement of the dosing, the subject receives a booster dose, comprising the administration of an oral dose of the immune enhancer on days 1 to 3, inclusive, followed by the vitamin supplement on days 4 to 28, inclusive. In another six months, the subject commences the dosing regime again.
[0245] The subject exhibits an improvement in their respiratory wellness.Example 8:
[0246] A healthy 30 year old male presents with a sore throat and fever. He is a long-term smoker, with a history of “colds going to the chest” i.e. sore throats followed after a few days to a week with cough productive of yellow sputum which lasts for week.
[0247] He is treated with a three-day course as follows: a. Oral enteric coated tablets containing 1011of inactivated NTHi. Two tablets a day for 3 days. b. Capsules containing Vit A (e.g. as Retinol palmitate 15,000ug (equivalent to 50,000 units of Vit A). One capsule a day for 3 days. c. -Capsules containing Vit D (as chlolecalciferal 250ug equivalent to 10,000 units of Vit D3) d. -Zinc (40 mg tablet one a day for 3 days.
[0248] His throat symptoms improve over a couple of days, and by one week a non-productive cough has resolved. Example 9
[0249] A 25 year old healthy woman is keen to prevent significant symptoms from intercurrent community virus infections such as influenza or Covid19.
[0250] She takes the following as daily therapy for 3 consecutive days each month: a. NTHi enteric coated tablets containing 1011inactivated NTHi. Two tablets a day. b. Vit A Capsules (e.g. as retinol palmitate 15,000ug).
[0251] At annual review, she claims a symptom free year from airways infection, except for 3-4 days of sore throat, dry cough and fatigue. She was tested PCR +ve for Covid19 – her PCR at 7 days was negative. At review, there were no residual symptoms, and no post covid syndrome.Example 10
[0252] A 75 year old man who has smoked 25 cigarettes a day for as long as she can remember, and had a “smokers cough” every morning for many years, has noted the last two years that on several occasions each year following a virus infection, she develops cough, purulent sputum and significant breathlessness requiring treatment with oral steroids and antibiotics.
[0253] He is treated with monthly courses of the following (daily for 3 days each month): a. Oral inactivated NTHi (dose per tablet as above), 2 tablets a day. b. Vit A (dose as above) one capsule a day c. Vit D (dose as above) one capsule a day
[0254] At 12 month review, his cough pattern has improved markedly, and the only post viral infection exacerbation caused no breathlessness, did not require specific treatment, and resolved within one week. Example 11
[0255] A healthy 40 year old non-smoking health worker is concerned to be protected against significant respiratory tract infections, including COVID-19. He takes monthly courses of oral inactivated NTHi (each course is 2 enteric coated tablets per day for 3 days, repeated every 4 weeks. Each tablet contains 10 to the power of 11 NTHi). By 12 months he has had one episode of Covid-19 (at 8 weeks into his oral NTHi courses), with symptoms mild and lasting 2 days, without additional therapy. His wife and 2 teenage children had Covid-19 at the same time, and were bed ridden for 5-7 days, and rapid test +ve for 15-17 days. Our Health worker was antigen negative by day 5.
[0256] Background. Our Health Worker was aware that oral inactivated NTHi was effective in subjects with damaged airways, including smokers, as these groups had dysbiotic microbiomes characterised by high numbers of NTHi (which are absent-very few in healthy non-smokers). He knew that he would NOT be aspirating significant numbers of NTHi into the gut to prime T cells in Peyer’s patches, sointuitively, oral NTHi would NOT deliver enhanced protection via T cell delivery for him. To determine whether oral NTHi would benefit him by delivering T cells via the blood stream, to the bronchus mucosa, he developed the following experiment.
[0257] The Experiment. Six health adult males were recruited - 3 took 3 monthly courses of oral inactivated NTHi (as above), while 3 took placebo tablets. Blood taken at days 34, 62, and 84 and cultured with crude NTHi antigen preparation or PHA (a non-specific stimulant of T cells). The NTHi antigen preparation was a sonicate of killed bacteria by the method of Davies et al (J.Clin. Path.27(1974)265- 268), all the information in this publication is incorporated herein by reference. Culture methods are described in: Clancy et al Clin Exp Immune 161(2010)127-33, all the information in this publication is incorporated herein by reference.
[0258] Response to stimulation in cpm were expressed as “stimulation Index for both test and placebo, with results of those given oral NTHi relevant to the placebo group, expressed as ratio of the means (in each 3 person group) of SI of active, divided by SI of placebo. Ratios of >2 were considered evidence of positive stimulation. The results were: DAY ANTIGEN STIMULATION PHA STIMULATION 34 2.2 1.5 62 2.0 55 84 40 95
[0259] The Interpretation. a. There is evidence that normal subjects can deliver both specific and non-specific T cells from Peyer’s patches to transit through the blood to relocate in the bronchus mucosa. The health worker was satisfied it was of value to take monthly courses of oral NTHi to maximise his chances of avoiding serious viral airway infection. b. The pattern of activation differed from the literature where identical study of chronic smokers (known to have dysbiotic colonisation withsignificant colonisation with NTHi: Clancy et al Clin Exp Immunol 161(2010)127-33). In smokers exposed to constant aspiration of NTHi, by day 34 significant stimulation by both antigen and PHA compared to placebos were detected. In normal adults with no risk factors (above), significant stimulation (ie detecting sensitised cells in transit) were not detected by PHA stimulation till day 62, and with antigen stimulation, day 84. c. Day 84, following the third monthly course of oral NTHi was different in the normal group compared to the smoker group - normal subjects without risk factors responded briskly to both PHA and antigen. In smokers there was little to no response at this time, due to immune suppression. The normal group had delayed detection of circulating antigen reactive and non specific T cells, meaning they required repeated oral immunisation to create the sensitisation required to migrate from Peyer’s patches, to the airway to provide protection. d. The Health Worker was protected from significant disease, compared to his family, due to enhanced T cell activation of learned innate immunity.
Claims
CLAIMS 1. A method for improving an individual’s health and or wellness wherein said individual does not present with, to any significant extent, a disease, condition or disorder of bacterial or viral origin, said method comprising the step of: administering to said individual an immunologically stimulatory preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal dosage.
2. A method according to claim 1, wherein the NTHi preparation is prepared from NTHi bacterium that are alive and viable, dead, attenuated or non-viable or inactivated or a mixture of these different states.
3. A method according to claim 1, wherein a substantial portion of the NTHi bacterium in the preparation are non-viable, dead bacteria.
4. A method according to claim 1, wherein the NTHi preparation is an attenuated or non-viable or inactivated NTHi strain.
5. An immune health and wellness enhancing formulation comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal dosage; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof.
6. An immune health and wellness enhancing formulation comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; andc. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
7. An immune health and wellness enhancing formulation comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
8. A formulation of anyone of claims 5 to 7, wherein the NTHi preparation is prepared from NTHi bacterium that are alive and viable, dead, attenuated or non- viable or inactivated or a mixture of these different states.
9. A formulation of anyone of claims 5 to 7, wherein a substantial portion of the NTHi bacterium in the preparation are non-viable, dead bacteria.
10. A formulation of anyone of claims 5 to 7, wherein the NTHi preparation is an attenuated or non-viable or inactivated NTHi strain.
11. A method for improving an individual’s health and or wellness wherein said individual is not otherwise suffering, to any significant extent, from a disease, condition or disorder of bacterial or viral origin, said method comprising the step of: administering to said individual a formulation as defined in any one of claims 5 to 10.
12. Use of an immunologically stimulatory preparation of a Haemophilus influenzae strain, preferably NTHi strain, for the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not otherwise suffering, to any significant extent, from a disease, condition or disorder of bacterial or viral origin.
13. Use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal dosage; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof for the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not otherwise suffering, to any significant extent, from a disease, condition or disorder of bacterial or viral origin.
14. Use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), for the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not otherwise suffering, to any significant extent, from a disease, condition or disorder of bacterial or viral origin.
15. Use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof;c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), for the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not otherwise suffering, to any significant extent, from a disease, condition or disorder of bacterial or viral origin.
16. A kit for improving an individual’s health and or wellness comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic.
17. A kit for improving an individual’s health and or wellness comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. a therapeutically effective amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof.
18. A method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual an immunologically stimulatory preparation of a Haemophilus influenzae strain, preferably NTHi strain, prepared for administration as an oral or nasal dosage.
19. Use of an immunologically stimulatory preparation of a Haemophilus influenzae strain, preferably NTHi strain, in the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
20. A health and wellness formulation suitable for administration to an individual for improving the health and or wellness of the individual, which formulation is prepared as an immunologically stimulatory preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells wherein the individual being treated by the formulation will not be suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
21. A method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof, prepared for administration as an oral or nasal dosage.
22. A method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal dosage; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof.
23. Use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and in the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
24. Use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and in the manufacture of a medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
25. An immune health and wellness enhancing formulation for use in a normal individual, said formulation comprising: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof, wherein the formulation is prepared for administration as an oral or nasal dosage.
26. An immune health and wellness enhancing formulation for use in a normal individual, said formulation comprising:a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal dosage; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof.
27. A method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), 28. A method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), wherein the formulation is prepared for administration as an oral or nasal dosage.
29. Use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), in the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
30. Use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), in the manufacture of a medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
31. An immune health and wellness enhancing formulation that comprises: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; andc. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
32. An immune health and wellness enhancing formulation that comprises: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; and c. an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), wherein the formulation is prepared for administration as an oral or nasal dosage.
33. A method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
34. A method for improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin, said method comprising the step of: administering to said individual:a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), wherein the formulation is prepared for administration as an oral or nasal dosage.
35. Use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), in the manufacture of a medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
36. Use of: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof;c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol), for the manufacture of an oral or nasal medicament for the improving an individual’s health and or wellness wherein said individual is not suffering from a mucosal disease, condition or disorder (preferably, a disease, condition or disorder of the respiratory tract) of bacterial or viral origin.
37. An immune health and wellness enhancing formulation that comprises: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
38. An immune health and wellness enhancing formulation that comprises: a. an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain with a dose range of from about 108to about 1015killed cells, prepared for administration as an oral or nasal therapeutic; and b. an immune system enhancing amount of vitamin A or a derivative thereof and optionally vitamin D or a derivative thereof; c. an immune system enhancing amount of vitamin C or a derivative thereof; and d. optionally, an immune system enhancing amount of zinc, or a zinc ionophore (such as a polyphenol).
39. A kit for improving an individual’s health and or wellness comprising: an immunologically effective preparation of a Haemophilus influenzae strain, preferably a NTHi strain, prepared for administration as an oral or nasal therapeutic.
Citation Information
Patent Citations
Non-adjuvenated vaccine
WO1986005691A1
Compositions and methods for treatment of mucosal infections
WO2001087332A1
Oral killed vaccines and method for providing same
WO2006017895A1
Non-typeable haemophilus influenzae vaccines and their uses
WO2010032141A2
Compositions and treatment of respiratory allergies
WO2016142448A1
